4.3. clinically significant prostate cancer. descriptor ‘clinically significant’ widely used differentiate pca may cause morbidity death specific patient types pca rarely do. distinction particularly important insignificant pca common . unless distinction made, cancers high risk over-treated, treatment risking harmful side effects patients. over-treatment insignificant pcas also criticised major drawback population-based screening individual early detection . although pathological factors often used delineate insignificant pca, definition significant vs. insignificant balance tumour patient factors. high-risk pca significant almost men, except life expectancy limited. low-risk pca insignificant almost men. pathological point view, large studies rp specimens isup grade group 1 disease, epe (0.3%) biochemical recurrence (3.5%) rare, seminal vesicle (sv) invasion lymph node (ln) metastasis occur . international society urological pathology grade group 1 disease rp therefore considered clinically insignificant. whilst isup grade group 1 bears hallmarks cancer histologically, isup grade group 1 rp behave clinically malignant fashion . important note studies showing absence metastasis isup grade group 1 done rp specimens; isup grade group 1 biopsy associated low risk developing metastasis disease-specific death, due under-sampling higher-grade component. contemporary retrospective study men ct1-t2 cn0 isup grade group 1 pca mpmri-targeted biopsy, 72% isup grade group ≥ 2, 9% isup grade group ≥ 3, 25% pt3a 4% pt3b subsequent rp . finally, modifications pca grading led grade shift past ten fifteen years; instance introduction isup 2005 led 20% pre-isup 2005 gs 6 tumours upgraded gs 7 higher, taken account interpreting older studies . current standard practice mri-targeted template biopsies improved diagnostic accuracy , however sampling error may still occur higher grade cancer could missed. especially considered case high psa density, high pathological biopsy tumour volume visible lesion mri, isup grade group 1 biopsy . another complexity defining insignificant cancer isup grade group 1 may progress higher grades time, becoming clinically significant later biopsy . therefore, although isup grade group 1 described clinically insignificant, important take account factors, including age, imaging prior biopsy adequate sampling core number. combined low-risk clinical factors (see table 4.3), isup grade group 1 represents low-risk pca recommended management options active surveillance (as) watchful waiting (ww) (see sections 6.2.1.1 & 6.2.1.2). proposed rename isup grade group 1 “tumours” omitting “cancer” label . moment, broad consensus yet exists changing disease taxonomy . instead, although probably insignificant cancer, appropriately observed. epidemiological autopsy data suggest proportion isup grade group 2 pca would remain undetectable man’s life therefore may over-treated. current guidelines deferred treatment may offered select patients intermediate-risk pca , clear evidence lacking appropriate selection criteria . recent papers defined clinically significant cancer differently, commonly using isup grade group 2 even isup grade group 3 above, demonstrating lack consensus evolution definition . papers provide one definition within single study . since insufficient data relate modern histological grading hard clinical endpoints, imperative authors define state studies believe cspca is, including exactly disease diagnosed. table 4.3: eau risk groups biochemical recurrence localised locally-advanced prostate cancer (based systematic biopsy) definitionlow-riskintermediate-riskhigh-riskpsa < 10 ng/mlpsa 10–20 ng/mlpsa > 20 ng/mlany psaand gs < 7 (isup grade 1)or gs 7 (isup grade 2/3)or gs > 7 (isup grade 4/5)any gs (any isup grade)and ct1-2a*or ct2b*or ct2c*ct3-4 cn+**localisedlocally advanced gs = gleason score; isup = international society urological pathology; psa = prostate-specific antigen.* based digital rectal examination.** based ct/bone scan.